GlassScriptPhysician profile
Jandark Yuseif
NPI 1114361284
$838.20
in general payments reported to CMS, 2019-2025
18 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2020: $180 · 2021: $490 · 2022: $168.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amarin Pharma, INC. | $124.05 | 2020-2021 | |
| Novo Nordisk INC | $114.34 | 2021-2022 | |
| Pfizer INC. | $86.19 | 2020-2021 | |
| Abbvie INC. | $83.92 | 2021 | |
| Lilly USA, LLC | $76.63 | 2020-2022 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $64.49 | 2021 | |
| Amgen INC. | $51.40 | 2021 | |
| Abbott Laboratories | $36.28 | 2021-2022 | |
| Bayer Healthcare Pharmaceuticals INC. | $33.38 | 2021 | |
| Astrazeneca Pharmaceuticals LP | $21.80 | 2020 | |
| Scilex Pharmaceuticals INC. | $20.57 | 2020 | |
| Irhythm Technologies, INC. | $19.76 | 2022 | |
| Merck Sharp & Dohme LLC | $18.90 | 2021 | |
| Novartis Pharmaceuticals Corporation | $18.84 | 2022 | |
| Janssen Pharmaceuticals, INC | $17.90 | 2020 |
Show all 18 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| E.R. Squibb & Sons, L.L.C. | $17.78 | 2021 | |
| Genentech USA, INC. | $16.78 | 2020 | |
| Astellas Pharma US INC | $15.19 | 2022 |
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jandark Yuseif listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.